Anatomical Pathology research
The Department of Anatomical Pathology’s main research areas involve collaborative projects on breast cancer, liver cancer, prostate cancer, melanoma, muscle disease and neurodegenerative diseases.
Professor McLean is a co-investigator on the Victorian Cancer Agency Melbourne Melanoma Project Award (2014- 2017), of over $3 million, led by Professor Grant McArthur of Peter MacCallum Cancer Centre. The Victorian Melanoma Service is also a co-investigator on this project.
In collaboration with her Monash University partner Professor Christina Mitchell, Professor Catriona MacLean was awarded:
- A five-year NHMRC Project Grant (2015-2019) of $916,231 entitled ‘Characterisation of autophagy deficiency in skeletal muscle homeostasis’ (CIA: Mitchell; CIC: McLean).
- A 12-month Cancer Council Victoria Grant-in-Aid for 2015 of $100,000 entitled ‘Characterisation of a novel oncogenic pathway in breast cancer’ (CIA: Mitchell; CIB: McLean). Studies will be aimed at looking at both primary and secondary tumour growth.
In 2014, trainee Dr Louise Jackett and Professor McLean were awarded first prize at the National Update in Pathology (a Royal College of Pathologists of Australia meeting) for their work on ‘Correlation of autopsy pathology with clinical diagnoses in life’. Appreciating the diagnoses that are missed provides an important contribution to improving clinical practice at Alfred Health.
In collaboration with The Alfred Neurosciences department, we published a paper in *Neurology, examining the neuropathology of a newly described syndrome CANVAS – cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome.Find out more
As part of a collaboration with Cancer Council, Victoria and International Colleagues at the University of Cambridge, we published work in Nature Communications and Human Molecular Genetics identifying new breast cancer risk gene loci and novel associations of regions of chromosome 2 with breast cancer.Find out more
Hepatobiliary and pancreatic: rare vascular tumor following treatment for hepatitis C with direct-acting antivirals
Britto K, Cheung W, Cameron R, Roberts SK, Kemp W
(2017), J Gastroenterol Hepatol, 32(12), 1912
The specimen that did not survive processing: ethical considerations pertaining to open disclosure
Adler NR, McLean CA, Gin D
(2017), J Am Acad Dermatol, 77(5), 988-90
The unregulated use of melanotan-II is of public health interest to Australian dermatologists
Adler NR, Dowling JP, Pan Y
(2017), Australas J Dermatol, 58(4), 327-9